SHARE TEXT
 
Scott B. Perlman, MD close
Scott B. Perlman, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Scott B. Perlman, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Perlman is the Chief of the Division of Nuclear Medicine and Director of the UW PET Imaging Center. His research interests include PET imaging in oncology and the use of positron emision tomography to evaluate inflammatory disease. Dr. Perlman provides a wide range of nuclear medicine services, including general nuclear medicine, nuclear cardiology, BMD and PET scans.

Specialties

Radiology

Computerized Tomography (CT) Scan

Fluoroscopic Studies

Image-guided Biopsy

Magnetic Resonance Imaging (MRI) Scan

Nuclear Medicine

PET/MRI Scan

Ultrasound

X-ray

Clinics

University Hospital
(608) 263-8340 | (800) 323-8942 | Map
Wisconsin Institutes for Medical Research
(608) 265-8731 | | Map

UW School of Medicine and Public Health

Department of Radiology

Professional Certifications and Education

Board Certification Nuclear Medicine
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School The Chicago Medical School, Chicago, IL

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Scarpelli M Zahm C Perlman S McNeel DG Jeraj R Liu G FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer . 2019 Jan 30;7(1):23
[PubMed ID: 30700328]
Lin C Harmon S Bradshaw T Eickhoff J Perlman S Liu G Jeraj R Response-to-repeatability of quantitative imaging features for longitudinal response assessment. Phys Med Biol . 2019 Jan 18;64(2):025019
[PubMed ID: 30566922]
Perk T Bradshaw T Chen S Im HJ Cho S Perlman S Liu G Jeraj R Automated classification of benign and malignant lesions in <sup>18</sup>F-NaF PET/CT images using machine learning. Phys Med Biol . 2018 Nov 20;63(22):225019
[PubMed ID: 30457118]
Perk T Chen S Harmon S Lin C Bradshaw T Perlman S Liu G Jeraj R A statistically optimized regional thresholding method (SORT) for bone lesion detection in <sup>18</sup>F-NaF PET/CT imaging. Phys Med Biol . 2018 Nov 20;63(22):225018
[PubMed ID: 30457117]
Weisman AJ Harmon SA Perk TG Eickhoff J Choyke PL Kurdziel KA Dahut WL Humm JL Apolo AB Larson SM Morris MJ Perlman SB Liu G Jeraj R Quantification of bone flare on <sup>18</sup>F-NaF PET/CT in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis . 2018 Nov 9;
[PubMed ID: 30413807]
Scarpelli M Rampurwala M Eickhoff J Carmichael L Heideman J Binger K Kolesar J Perlman S Harrow K Dukart G Liang C Jeraj R Liu G Bruce JY Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemother Pharmacol . 2018 Aug;82(2):211-219
[PubMed ID: 29802443]
Scarpelli M Simoncic U Perlman S Liu G Jeraj R Dynamic <sup>18</sup>F-FLT PET imaging of spatiotemporal changes in tumor cell proliferation and vasculature reveals the mechanistic actions of anti-angiogenic therapy. Phys Med Biol . 2018 Jul 27;63(15):155008
[PubMed ID: 29978839]
Scarpelli M Eickhoff J Cuna E Perlman S Jeraj R Optimal transformations leading to normal distributions of positron emission tomography standardized uptake values. Phys Med Biol . 2018 Jan 30;63(3):035021
[PubMed ID: 29235988]
Scarpelli M Bruce JY Carmichael L Eickhoff J Kolesar J Perlman S Jeraj R Liu G <sup>18</sup>F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. Cancer Chemother Pharmacol . 2016 Dec;78(6):1245-1252
[PubMed ID: 27817059]
Lin C Bradshaw T Perk T Harmon S Eickhoff J Jallow N Choyke PL Dahut WL Larson S Humm JL Perlman S Apolo AB Morris MJ Liu G Jeraj R Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. J Nucl Med . 2016 Dec;57(12):1872-1879
[PubMed ID: 27445292]
Simoncic U Perlman S Liu G Jeraj R Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer. Nucl Med Commun . 2015 Dec;36(12):1174-80
[PubMed ID: 26378490]
Bruce JY Scully PC Carmichael LL Eickhoff JC Perlman SB Kolesar JM Heideman JL Jeraj R Liu G Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer Chemother Pharmacol . 2015 Jul;76(1):187-95
[PubMed ID: 26021741]
Simoncic U Perlman S Liu G Staab MJ Straus JE Jeraj R Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer . 2015 Feb;13(1):e7-e17
[PubMed ID: 25128349]
Muzahir S Jeraj R Liu G Hall LT Rio AM Perk T Jaskowiak C Perlman SB Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. Am J Nucl Med Mol Imaging . 2015;5(2):162-8
[PubMed ID: 25973337]
Lubner SJ Mullvain J Perlman S Pishvaian M Mortimer J Oliver K Heideman J Hall L Weichert J Liu G A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies. Cancer Invest . 2015;33(10):483-9
[PubMed ID: 26536061]
Schneider DF Sonderman PE Jones MF Ojomo KA Chen H Jaume JC Elson DF Perlman SB Sippel RS Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol . 2014 Dec;21(13):4174-80
[PubMed ID: 25001092]
Bates ML Farrell ET Drezdon A Jacobson JE Perlman SB Eldridge MW Hypoxia and exercise increase the transpulmonary passage of 99mTc-labeled albumin particles in humans. PLoS One . 2014;9(7):e101146
[PubMed ID: 25013985]
Bruce JY Kolesar JM Hammers H Stein MN Carmichael L Eickhoff J Johnston SA Binger KA Heideman JL Perlman SB Jeraj R Liu G A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol . 2014 Mar;73(3):485-93
[PubMed ID: 24414551]
Perlman SB Hall BS Reichelderfer M PET/CT imaging of inflammatory bowel disease. Semin Nucl Med . 2013 Nov;43(6):420-6
[PubMed ID: 24094709]
Vanderhoek M Perlman SB Jeraj R Impact of different standardized uptake value measures on PET-based quantification of treatment response. J Nucl Med . 2013 Aug;54(8):1188-94
[PubMed ID: 23776199]